Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654635 | 0.86 | KMO (0.36) | MCL1 | |
| SCHEMBL1008684 | 0.83 | XIAP (0.38) | MCL1 | |
| SCHEMBL1064613 | 0.80 | MAP2K1 (0.33) | MAP2K1 | |
| SCHEMBL2656075 | 0.79 | SIRT2 (0.44) | MCL1LNPEPCMA1 | |
| SCHEMBL2656919 | 0.79 | SIRT2 (0.44) | MCL1LNPEPCMA1 | |
| SCHEMBL2655456 | 0.79 | SIRT2 (0.44) | MCL1LNPEPCMA1 | |
| SCHEMBL2657088 | 0.78 | MCL1 (0.36) | MCL1AKR1C3AKR1C2 | |
| SCHEMBL2657605 | 0.78 | MCL1 (0.36) | MCL1AKR1C3AKR1C2 | |
| SCHEMBL1008308 | 0.78 | MCL1 (0.36) | MCL1AKR1C3AKR1C2 | |
| SCHEMBL2656662 | 0.76 | RXRA (0.39) | MRGPRX4LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | MRGPRX4 3192/4885MAP2K1 922/4885P2RX7 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.